During previous monkeypox outbreaks, severe disease manifestations and poor outcomes have been reported among persons with HIV infection, particularly those with AIDS.
A U.S. CDC Morbidity and Mortality Weekly Report (MMWR) issued on October 26, 2022, summarizes findings from CDC clinical consultations provided for 57 adult patients who were hospitalized with severe manifestations of monkeypox from August 10–October 10, 2022.
Severe Monkeypox Impacts People with HIV
Disparities ID’d in Dispensing of Oral Antivirals for COVID-19
Substantial disparities seen in dispensing rates in high social-vulnerability zip codes versus medium-, low-vulnerability zip codes
Pooled Risk for Thrombocytopenia Increased After ChAdOx1-S Vaccine
Pooled 30 percent increased risk for thrombocytopenia seen after first dose of ChAdOx1-S versus BNT162b2
Overall Symptoms After BNT162b2, Other Vaccines Comparable in <5s
Injection-site, musculoskeletal, dermatologic, otolaryngologic symptoms more frequent; general symptoms and fever less frequent with BNT162b2 in children younger than 5 years of age